about
Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21,715 women participating in the UK Collaborative Trial of Ovarian Cancer ScreeningCommentary: Dr John Brownlee MA, MD, DSc, DPH (Cantab), FRFPS, FSS, FRMetS (1868-1927), public health officer, geneticist, epidemiologist and medical statistician.Musicians' playing-related musculoskeletal disorders: an examination of risk factors.Dirichlet negative multinomial regression for overdispersed correlated count data.The versatility of multi-state models for the analysis of longitudinal data with unobservable features.Some comments on analysis techniques for censored water quality data.Discussing randomised clinical trials of cancer therapy: evaluation of a Cancer Research UK training programme.Regression analysis of overdispersed correlated count data with subject specific covariates.Bias in 2-part mixed models for longitudinal semicontinuous data.Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies.A semi-competing risks model for data with interval-censoring and informative observation: an application to the MRC cognitive function and ageing studyThe use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients.Methodological issues in randomized controlled trials.Numerical scoring for the BILAG-2004 indexProspective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosusWoods and Russell, Hill, and the emergence of medical statistics.Two-stage meta-analysis of survival data from individual participants using percentile ratios.Likelihood estimation for a longitudinal negative binomial regression model with missing outcomes.A multistate model for events defined by prolonged observationThe attitudes of 1066 patients with cancer towards participation in randomised clinical trials.One-stage parametric meta-analysis of time-to-event outcomes'A memorandum on the Present Position and Prospects of Medical Statistics and Epidemiology' by Major Greenwood.Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial.Clinicians' attitudes towards clinical trials of cancer therapyMonitoring the evolutionary process of quality: risk-adjusted charting to track outcomes in intensive care.International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.TNFalpha polymorphisms and risk of psoriatic arthritis.Predictors for radiological damage in psoriatic arthritis: results from a single centre.Hilda Mary Woods MBE, DSc, LRAM, FSS (1892-1971): reflections on a Fellow of the Royal Statistical SocietyThe BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patientsShort-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study.Assessment of cognitive function in systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis by computerized neuropsychological tests.Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study.Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study.The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally.Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.Enduring impact of communication skills training: results of a 12-month follow-up.Drivers and barriers to patient participation in RCTs.British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS).
P50
Q24608602-C0E5E819-C0B6-461C-9B90-0E5E71D40BD6Q30353866-0B0A120D-3107-445A-8A29-09D62E2EC12BQ30538285-A44241F2-3CC3-455A-97D1-033373F03069Q30580671-FE6CD520-58A2-404A-AB85-65C62C8CDC0FQ30580814-AE345498-9ACE-4679-9450-7C402B118DA1Q30696610-2255F303-2B4C-47C2-BC7F-857DD76AEC5CQ30856369-D048E35B-6C50-468F-A9C9-D9F9C96A2233Q30992837-8A8460E4-5273-4480-BC9E-62CB58B5D756Q33399008-7E9893C4-FC55-4B71-9B9D-256257899F13Q33623219-1E3DC747-800A-4AE5-9015-5562FE70EBE3Q33785089-1550BD7A-178F-4A35-8C13-0BA252BCC979Q33796222-7BE4EB0B-7178-4F24-9838-A6843E0CCC8BQ33946295-EBBF78D0-8909-4F09-A068-25C8DB061F25Q34056232-E9316891-ADAC-4F73-A32D-351E8A681D91Q34087831-723104C9-2A4C-41E0-BCD2-85F5646696E4Q34119979-A0E71292-61FE-4327-9F95-BEF34639BD8BQ34349070-5FF7CCD0-BFC1-45B1-82CA-960A8F874436Q34401622-B21D02E3-593B-4F41-BAE0-DF82FEBE0905Q34425372-E3811128-8F8E-433B-87D3-8BBB59BD56FAQ34433816-6CF287B1-47AF-4A33-86EC-B00D36DE1D0BQ34486888-7EDADF33-9F53-420C-AB46-6FC295C56124Q34535011-B75CCA00-B56C-42CB-B3C5-AA4329C37A9EQ34552715-54AE02B8-2E67-4ED2-9BF6-750A8C92CEEBQ35006767-51E1CB5F-18DD-431C-8085-206B7BF4CBFDQ35148706-432418B5-B0A5-4CC4-9E91-DCF19E5F7C81Q35179618-82BE2B2B-0932-42CD-89B2-F8A1E19BB8F9Q35637359-69C42EBE-C073-4A08-8275-0948EC9413D8Q35760034-35617DA0-2BDE-4298-B9B4-04CA50D27F24Q36220390-95D5F231-9CDE-49C1-BEB3-0D92B1CAFA77Q36252764-D1E93A4E-8268-47CA-B221-52C43935EB29Q36307414-2B498030-13C5-4EB4-8530-E255D121BB14Q36307418-C4CA4E05-0DAE-4597-8DFF-F45A25F6E1BEQ36307423-D54D0615-1D32-43D8-8687-757AA21055FFQ36307429-AEB5058D-4B75-435F-97D2-4C8E63F19796Q36331877-A8BC7018-A904-4290-8C98-A1B299678D69Q36332517-BC4D1640-7289-4402-8A65-8080D84FFF93Q36671286-5B996A11-2DC7-4CFF-B042-8BF9C71DDFDEQ36775343-05D89AC7-02FF-4D51-990B-3843967C537AQ37137162-C3BD4D62-34D6-41DD-B5FB-3DA4FB678F0BQ37150616-236632FB-4D8E-42A9-A32F-C4056070C93B
P50
subject
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Vernon Farewell
@ast
Vernon Farewell
@en
Vernon Farewell
@es
Vernon Farewell
@nl
Vernon Farewell
@sl
type
label
Vernon Farewell
@ast
Vernon Farewell
@en
Vernon Farewell
@es
Vernon Farewell
@nl
Vernon Farewell
@sl
prefLabel
Vernon Farewell
@ast
Vernon Farewell
@en
Vernon Farewell
@es
Vernon Farewell
@nl
Vernon Farewell
@sl
P1006
P214
P244
P906
P950
P1006
P106
P1153
7005718187
P21
P214
P244
P31
P496
0000-0001-6704-5295
P569
1951-01-01T00:00:00Z
P734
P735
P7859
lccn-n86831864